

Autoimmune Lymphoproliferative

[View the current Autoimmune Lymphoproliferative InDepth page on BioPortfolio.com \(PDF\)](#)
(http://www.bioportfolio.com/indepth/Autoimmune_Lymphoproliferative.html) - Regularly Updated.

Recent Publications on Autoimmune Lymphoproliferative:



- [Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome.](#)
*Autoimmune lymphoproliferative syndrome (ALPS) is a genetic disorder of...*14th October, 2009
University Children's Hospital, Beograd (Belgrade), Republic of Serbia.- *Pediatr Blood Cancer.* 2009 Dec;53(6):1117-9. ([DOI Direct Link](#))
- [Splenectomy in two children with autoimmune lymphoproliferative syndrome and massive splenomegaly.](#)
*Treatment of patients with ALPS has varied but presently there is no...*14th October, 2009
Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus,- *Pediatr Blood Cancer.* 2009 Dec;53(6):1124-6. ([DOI Direct Link](#))
- [Autoimmune lymphoproliferative syndrome-like syndrome presented as lupus-like syndrome with mycobacterial joint infection evolved into the lymphoma.](#)
*The autoimmune lymphoproliferative syndrome (ALPS) and ALPS-like syndrome...*25th September, 2009
Department of Internal Medicine, Yeungnam University College of Medicine,- *Rheumatol Int.* 2009 Mar;29(5):569-73. Epub 2008 Sep 27. ([DOI Direct Link](#))
- [Fas stimulation of T lymphocytes promotes rapid intercellular exchange of death signals via membrane nanotubes.](#)
*The Fas/CD95 surface receptor mediates rapid death of various cell types,...*23rd September, 2009
[1] University of Manchester, Royal Manchester Children's Hospital,- *Cell Res.* 2009 Sep 22. ([DOI Direct Link](#))
- [Applications of flow cytometry for the study of primary immune deficiencies.](#)
*PURPOSE OF REVIEW: This review focuses on the current applications of flow...*2nd July, 2009
Immunology Service, Department of Laboratory Medicine, National Institutes- *Curr Opin Allergy Clin Immunol.* 2008 Dec;8(6):499-509. ([DOI Direct Link](#))
- [Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants.](#)
*We report a case series of four infants with severe autoimmune haemolytic...*20th June, 2009
Haematology Unit, G Gaslini Children's Institute, Genova, Italy.- *Br J Haematol.* 2009 Apr;145(1):96-100. Epub 2009 Feb 4. ([DOI Direct Link](#))
- [Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome.](#)
*We hypothesized that sirolimus, an mTOR inhibitor, may be effective in...*20th June, 2009

Pediatric Hematology and Oncology, Children's Hospital of Philadelphia,- Br J Haematol. 2009 Apr;145(1):101-6. Epub 2009 Feb 4. ([DOI Direct Link](#))

- [The technological transformation of patient-driven human immunology research.](#)
*New scientific technologies applied to patients with rare diseases are...*10th June, 2009
National Institute of Allergy and Infectious Diseases, National Institutes- Immunol Res. 2009;43(1-3):167-71. ([DOI Direct Link](#))
- [Pulmonary thromboembolism in childhood: a single-center experience from Turkey.](#)
*OBJECTIVE: This study was designed to evaluate the clinical...*15th May, 2009
Hacettepe University Faculty of Medicine, Ihsan Dogramaci Children's- Heart Lung. 2009 Jan-Feb;38(1):56-65. Epub 2008 Aug 23. ([DOI Direct Link](#))
- [Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome \(ALPS\).](#)
*BACKGROUND: ALPS is a disorder of apoptosis resulting in accumulation of...*6th May, 2009
Laboratory of Clinical Infectious Diseases, NIAID, and Clinical Center,- Pediatr Blood Cancer. 2009 Jul;52(7):847-52. ([DOI Direct Link](#))
- [FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome \(ALPS\) associated with FAS loss of function.](#)
*Autoimmune lymphoproliferative syndrome (ALPS) is characterized by...*2nd May, 2009
Inserm U768, Paris, France.- Blood. 2009 Mar 26;113(13):3027-30. Epub 2009 Jan 27. ([DOI Direct Link](#))
- [Residual CD95-pathway function in children with autoimmune lymphoproliferative syndrome is independent from clinical state and genotype of CD95 mutation.](#)
*Human autoimmune lymphoproliferative syndrome (ALPS) is caused by...*1st May, 2009
Children's Hospital, University of Ulm, Ulm 89073, Germany.- Pediatr Res. 2009 Feb;65(2):163-8. ([DOI Direct Link](#))
- [Valproic acid \(VPA\), a histone deacetylase \(HDAC\) inhibitor, diminishes lymphoproliferation in the Fas-deficient MRL/lpr\(-/-\) murine model of autoimmune lymphoproliferative syndrome \(ALPS\).](#)
*OBJECTIVE: Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of...*10th April, 2009
Laboratory of Clinical Infectious Diseases, National Institutes of Allergy- Exp Hematol. 2009 Apr;37(4):487-94. Epub 2009 Feb 12. ([DOI Direct Link](#))
- [Autoimmune manifestations in primary immune deficiencies.](#)
*Autoimmune manifestations have long been perceived as paradoxical in...*3rd April, 2009
Universite Paris Descartes, UPRES EA 4058, Paris, France.- Autoimmun Rev. 2009 Feb;8(4):332-6. Epub 2008 Nov 24. ([DOI Direct Link](#))
- [\[New therapeutic perspectives for arsenic: from acute promyelocytic leukemia to autoimmune diseases\]](#)
*Since 1996, arsenic trioxide (As₂O₃) is used to treat patients with acute...*28th January, 2009
CNRS FRE 2937, Institut Andre Lwoff, 7 rue Guy Moquet, 94801 Villejuif- Med Sci (Paris). 2008 Nov;24(11):967-71.

Autoimmune Lymphoproliferative Patents:



- 7196083- [Heteropolycyclic inhibitors of protein kinases](#)
- 7317029- [3,5-disubstituted-\[1,2,4\]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof](#)

- 7348003- [Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors](#)
- 7361341- [Methods of treating cancer using antibodies that immunospecifically bind to trail receptors](#)
- 7368527- [HADDE71 polypeptides](#)
- 7368531- [Human secreted proteins](#)
- 7378098- [CXC chemokine receptor 4 agonist peptides](#)
- 7390799- [Apoptosis promoters](#)
- 7393942- [Nucleic acids encoding mutant forms of Fas ligand](#)
- 7396662- [C-type lectin polypeptides](#)
- 7411051- [Antibodies to HDPPA04 polypeptide](#)
- 7294713- [Antisense IAP oligonucleotides and uses thereof](#)
- 7288556- [Antiproliferative 1,2,3-thiadiazole compounds](#)
- 7276477- [Crystals of etanercept and methods of making thereof](#)
- 7217807- [Bioinformatically detectable group of novel HIV regulatory genes and uses thereof](#)
- 7220739- [Therapeutic application of pro-apoptotic benzodiazepines](#)
- 7226927- [Substituted 2-aryl-4-arylamino-pyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof](#)
- 7235372- [Use of neuronal apoptosis inhibitor protein \(NAIP\)](#)
- 7235674- [Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof](#)
- 7256219- [Multifluoro-substituted chalcones and analogs as activators of caspases and inducers of apoptosis and the use thereof](#)
- 7267960- [Antagonists and agonists of LDCAM and methods of use](#)
- 7273609- [Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L](#)
- 7276344- [Methods for using the osteoclastogenesis inhibitory factor \(OCIF\) protein](#)
- 7276348- [Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof](#)
- 7423018- [Kinesin-like proteins and methods of use](#)
- 7435718- [CXCR4 antagonist treatment of hematopoietic cells](#)
- 7541441- [Antibodies that specifically bind to TL5](#)
- 7566533- [Clinically intelligent diagnostic devices and methods](#)
- 7572788- [Compositions and methods relating to novel compounds and targets thereof](#)
- 7585653- [Oncokine fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same](#)
- 7589112- [Methylene urea derivatives](#)
- 7592143- [Methods of treating diseases responsive to induction of apoptosis and screening assays](#)
- 7604944- [Oncokine fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same](#)
- 7605237- [High affinity human antibodies to human IL-4 receptor](#)
- 7608693- [High affinity human antibodies to human IL-4 receptor](#)
- 7615380- [Methods for modulating an immune response by modulating KRC activity](#)
- 7528164- [Substituted 4-aryl-4h-pyrrolo\[2,3-h\]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof](#)
- 7524663- [Covalently reactive transition state analogs and methods of use thereof](#)
- 7510710- [Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor](#)
- 7435750- [Method of using substituted 3-aryl-5-aryl-\[1,2,4\]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof](#)
- 7438910- [Therapeutic human anti-IL1-R1 monoclonal antibody](#)
- 7455860- [Dietary supplement formulation for controlling inflammation and cancer](#)
- 7465450- [Methods and compositions relating to anti-interleukin-4 receptor antibodies](#)
- 7468268- [Nucleic acid molecules encoding osteoclastogenesis inhibitory factor proteins](#)
- 7473683- [Nonpolar thymidine analogs](#)
- 7476683- [Glycinamide derivatives as raf-kinase inhibitors](#)

- 7476741- [Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof](#)
- 7507542- [Method for regulating immune function using the FOXP3 protein](#)
- 7507762- [Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof](#)
- 7618975- [4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

